Original article

Serum Interleukin - 6 level among Sudanese Patients with Chronic kidney disease

Safaa I.A Nasr, Rabab A.M Adam, Hala M.M Ibrahim, Afra S.A Abdelgadir, Ibrahim Alkider, Solomon M. Gamde, Simon P. Abriba

*Department of Hematology and Immunohematology, Faculty of Medical Laboratory Science, Sudan International University
†Department of Medical Laboratory Science, Faculty of Health Sciences, Bingham University Karu, Nigeria

1. Introduction

Chronic Kidney Disease (CKD) is an irreversible loss of the kidney functions which is fatal in the absence of prescribed dialysis or kidney transplant (1,2). Nowadays, there are increasing evidences that associate CKD to the disruption in immune responses. CKD affects over 800 million individual worldwide and it is fast becoming a public health concern due to the high mortality and growing number of patients who required renal replacement therapy (3). Numerous systemic and local insults, including infections, hypoxemia, nephrotoxin, immune complexes dysregulation, advanced glycation end products are known to stimulate the kidney to produce systemic interleukin-6 (IL-6) (4,5). Some studies (6,7) have reported high plasma IL-6 level in CKD patients. Interleukin-6 accelerates the progression of CKD not only by aggravating kidney injury as described above but also by initiating its complications, especially the chronic vascular disease (CVD).

ARTICLE INFO

Keywords:
Interleukin-6
Chronic Kidney Disease
Inflammation, and Hemoglobin.

ABSTRACT

Background: High plasma interleukin-6 is common in chronic kidney disease patients due to chronic stress, prolonged inflammation, and fluid overload. However, conflicting opinions still exist. Moreover, the effects of age, sex, and ethnicity on interleukin-6 level in chronic kidney disease is not known. Aim: This study aimed to determine interleukin-6 level in chronic kidney disease patients in Khartoum, Sudan. Methods: This is a cross-sectional laboratory based study. A total of 88 participants consisting of 44 chronic kidney disease patients and 44 apparently healthy control. Of the 44 chronic kidney disease patients, 27 (61%) were male and 17 (39%) female. According to their age, 15 (34%) ≤ 40 years and 29 (66%) > 40 years old. Concerning the duration of disease, 31 (70%) were ≤ 2 years and 13 (30%) were > 2 years. Hemoglobin and interleukin-6 concentration were determined using enzyme linked immunosorbent assay. Results: Plasma interleukin-6 levels was significantly (p= 0.011) elevated in chronic kidney disease (Mean ± SD = 51.72 ± 9.63) compared to control group (Mean ± SD = 24.77±3.27). When hemoglobin was considered, interleukin -6 correlates negatively with significant difference (Correlation coefficient = -0.0364, p = 0.033). However, there was no statistical significant difference among the sex, age, and duration of the disease. Conclusion: Interleukin -6 level was significantly elevated in chronic kidney disease. There was no significant difference in the interleukin -6 level among the sex, age, and duration of the disease. When hemoglobin was considered, there was a negative correlation with interleukin -6.

MATERIALS AND METHOD

Study design and Population

This was a cross-sectional laboratory-based study conducted in August- September 2020 consisting of a control group of forty-four apparently healthy participants, 27 (61.4%) were male, and a test group of forty-four CKD patients, 17 (38.64%) were female, proved by hemodialysis in Alrebath hospital Khartoum, Sudan.

The study participants were recruited from the Alrebath hospital Khartoum, Sudan. The apparently healthy volunteers for the control without CKD, diabetes mellitus, hypertension, viral infections (HIV, HBV, and HCV) or other known risk factors for CKD were included for the study. Personal data was obtained by standard questionnaire designed for dialysis patients.

Ethical clearance

The study received ethical clearance from both the ethical review committees at the Faculty of Medical Laboratory Science, Sudan International University and Alrebath hospital, Khartoum, Sudan. Informed consent was obtained from all the study participants.

*Corresponding Author: Solomon Matthias Gamde
email: solomonmatthias85@gmail.com
ORCID: http://orcid/0000-0002-7631-8782

© Copyright 2023 BioMedSciDirect Publications IJBMR - All rights reserved.
Sample Preparation and Procedure

On a 5 ml EDTA container, venous blood was collected by single non traumatic venipuncture. Haemoglobin was measured by automatic blood counter (Sysmex KX-21N) for both CKD patients and control group. The centrifuged plasma was harvested into a plain container for IL-6 estimation using enzyme linked immunosorbent assay (ELISA).

Principle of Enzyme Linked Immunosorbent Assay

This involves the reaction of an antibody with an antigen and a detection system to determine if a reaction has occurred which involves Binding of the test molecule or organism to a solid support e.g. micro titer plate.

Statistical analysis

The data obtained were categorized into different groups and analyzed by statistical using computer program statistical package for social science (SPSS), used F-test (ANOVA) and T-test. Analyzed data was represented in tables and figures.

RESULT

Our data (Table 1) showed that IL-6 was significantly (p value 0.011) increased in CKD group (Mean±SD =51.72±9.63) compared to control (Mean±SD=24.77±3.27). However, there was no statistical significant (P > 0.05) difference in IL-6 levels among the age groups, gender, and duration of the disease (Table 2).

The characteristics of the demographic data and mean hemoglobin (Hb) concentration in CKD are given in Table 3. Hb Mean ± SD = 10.5±1.29, age group Mean ± SD = 46.5±13.7, and Mean ± SD = 1.97±0.74.

Figure 1 showed the percentages of the age groups, gender, and duration of disease.

In figure 2, hemoglobin correlates negatively with IL-6 level (correlation coefficient = -0.0364, P value<0.033).

Table 1: Study Interleukin-6 level

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Group</th>
<th>Number</th>
<th>Mean ± SD</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-6 levels</td>
<td>CKD case</td>
<td>44</td>
<td>51.72±9.63</td>
<td>0.011</td>
</tr>
<tr>
<td>Control</td>
<td>44</td>
<td>24.77±3.27</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Characteristics of CKD patients

<table>
<thead>
<tr>
<th>Variables</th>
<th>Gender</th>
<th>Number</th>
<th>Mean ± SD</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Male</td>
<td>27</td>
<td>50.5±15.2</td>
<td>0.601</td>
</tr>
<tr>
<td>Female</td>
<td>17</td>
<td>53.5±15.03</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>&lt;40 Years</td>
<td>15</td>
<td>56.2±21.30</td>
<td>0.772</td>
</tr>
<tr>
<td>&gt;40 Years</td>
<td>29</td>
<td>49.9±9.09</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration</td>
<td>≤2 Years</td>
<td>31</td>
<td>55.6±12.81</td>
<td>0.742</td>
</tr>
<tr>
<td>&gt;2 Years</td>
<td>13</td>
<td>42.3±11.62</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3: Mean Hb and Demographic data

<table>
<thead>
<tr>
<th>Variables</th>
<th>Minimum</th>
<th>Maximum</th>
<th>Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age group</td>
<td>72.0</td>
<td>72.0</td>
<td>46.5±13.7</td>
</tr>
<tr>
<td>Duration</td>
<td>1.00</td>
<td>3.00</td>
<td>3.97±0.74</td>
</tr>
<tr>
<td>Hb</td>
<td>7.30</td>
<td>13.6</td>
<td>10.5±1.29</td>
</tr>
</tbody>
</table>

Figure 1: Percentages of the age groups, gender, and duration of the disease

Figure 2: Correlation of IL-6 and Hb levels in CKD

DISCUSSION

Mortality due to CKD is a global problem due to high prevalence of CKD risk factors. The present study investigated the possible effect of Interleukin (IL)-6 in CKD patients on hemodialysis. Our result showed that the plasma IL-6 was significantly (P =0.011) elevated in CKD patients (Mean±SD=51.72±9.63) compared to control (Mean±SD=24.77±3.27). Our finding is in tandem with previous study that documented interleukin-6 as a proinflammatory and anti-inflammatory cytokines which is elevated in chronic kidney disease (10).

In figure 2, hemoglobin correlates negatively with IL-6 level (correlation coefficient = -0.0364, P value<0.033).

CONCLUSION

Based on these finding, interleukin-6 level was significantly raised in Chronic Kidney Disease. there was no significant association in IL-6 among the age groups, gender, and duration of the disease. Our data also showed a negatively significant association between Hb and interleukin -6 level in the study population.

ACKNOWLEDGEMENT

Our gratitude goes to the Staff in Alrebat Hospital who supported in the sample collection and Khartoum University Institute of Endemic Disease.

Conflict of interest: None declared.
Funding: Nothing to declare.
Authors’ Contribution: All authors were equally involved in data collection, analysis, manuscript preparation, revision and finalization.

References


